Pluristem Therapeutics (PSTI)
Pluristem Therapeutics Revenues: 0.154M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
PSTI Revenues Rankings
| Overall | 1st percentile | 4386 of 4432 |
| Sector | 4th percentile | 449 of 471 in Healthcare |
| Industry | 7th percentile | 122 of 132 in Biotechnology |
PSTI Revenues Range, Past 5 Years
| Minimum | 0.154M | Sep 2011 |
| Maximum | 0.154M | Sep 2011 |
| Average | 0.154M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these PSTI related companies
PSTI News
Equity Briefing : Pluristem's PLX cells may change bone marrow transplantation as well as other potential indications
May 23, 9:14AM Thomson Reuters ONE
May 23, 9:14AM Thomson Reuters ONE
Needham & Company Starts Pluristem Therapeutics (PSTI) at Buy; Leading Cell Therapy Platform
May 22, 7:22AM Street Insider
May 22, 7:22AM Street Insider
Pluristem Therapeutics announces preclinical results of PLacental eXpanded administration ($PSTI)http://stks.co/3tmX
about 13 days ago by UpGradedStrategies
about 13 days ago by UpGradedStrategies
RT @fhmmax $ARNA $PSTI shart spiking over M&A rumor. * I am long but the MA must be in ur head, Stop it
about 18 days ago by behconsult
about 18 days ago by behconsult
RT @fhmmax $ARNA $PSTI shart spiking over M&A rumor/CUT IT OUT. Post a link. Too many amateurs. No 1 has ever changed stck prce via stkwts
about 18 days ago by behconsult
about 18 days ago by behconsult
$PSTI 200 Day SMA Cross - Price crossed below 200 day SMA (2.5006). Confirmed by volume.
about 22 days ago by TradeIdeasQuant
about 22 days ago by TradeIdeasQuant
$PSTI with cautious optimism I recommend a close watch on this stock...huge upside potential with fast track for FDA approval
about 22 days ago by Creyedr
about 22 days ago by Creyedr
Unusual 11 Mid-Day Movers 05/09: (SODA) (NKBP) (HTH) Higher; (MEMS) (CQB) (AMRS) Lower
May 09, 2:25PM Street Insider
May 09, 2:25PM Street Insider
You know the mkt is upside down, and full of fear when $PSTI is up alot
about 22 days ago by rosswhiting
about 22 days ago by rosswhiting
$PSTI will not only create a good return on my investment but has helped humanity as well. Hopefully $SNSS will do the same.
about 23 days ago by bluesfreak
about 23 days ago by bluesfreak
$PSTI great story on PSTI drug use, healing 7 year old girl with compassionate use... and it worked. Should move today.
about 23 days ago by mentholatum
about 23 days ago by mentholatum
Pluristem (PSTI) PLX Cells Led to Strong Recovery in Seven Year-Old Bone Marrow Patient
May 09, 7:43AM Street Insider
May 09, 7:43AM Street Insider
Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure
May 09, 7:30AM GlobeNewswire
May 09, 7:30AM GlobeNewswire
Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in Intermittent Claudication
Apr 17, 7:04AM Benzinga
Apr 17, 7:04AM Benzinga
$PSTI filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/32sO
about 70 days ago by MarketBrief
about 70 days ago by MarketBrief
$PSTI filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/31JO
about 71 days ago by MarketBrief
about 71 days ago by MarketBrief
$PSTI..this is big: Pluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction (AMI) in Animal Trial...only the beginning!!
about 73 days ago by Creyedr
about 73 days ago by Creyedr
$PSTI $2.26 news- Pluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction (AMI) in Animal TrialGlobeNewswire
about 73 days ago by wallstreetlive
about 73 days ago by wallstreetlive
Pluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction in Animal Trial
Mar 20, 7:03AM Benzinga
Mar 20, 7:03AM Benzinga
Pluristem's PLX Cells Effective in Treatment of Acute Myocardial Infarction (AMI) in Animal Trial
Mar 20, 7:00AM GlobeNewswire
Mar 20, 7:00AM GlobeNewswire
$PSTI forms bearish "Flag" chart pattern. http://stks.co/2unb
about 76 days ago by RecogniaEvents
about 76 days ago by RecogniaEvents
@abubnic any insight on $PSTI??? I am seeing an incredible amount of stem cell research but does it translate into profits for this stock?
about 100 days ago by Creyedr
about 100 days ago by Creyedr
Pluristem Therapeutics (PSTI) Announces Plan to Expand Research & Development of Radiation Exposure Treatment
Feb 07, 6:49AM Street Insider
Feb 07, 6:49AM Street Insider
$PSTI http://stks.co/1oWF The Volatility Squeeze and the action...nice for TA lovers, good combo of TA & Bio fundamental
about 146 days ago by gantosj
about 146 days ago by gantosj
$PSTI http://stks.co/1oJX Breaking out the triangle
looking for the volatility
squeeze & breaking out the
BB & 200MA
about 146 days ago by gantosj
about 146 days ago by gantosj
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PSTI | 2.38 | -0.05 | -2.06% | 108.06M |
| PST | 28.07 | -0.23 | -0.81% | |
| PSSI | 20.24 | +0.18 | +0.90% | 1.029B |
| POR | 25.15 | +0.09 | +0.36% | 1.889B |
| POPE | 48.69 | +0.69 | +1.44% | 211.68M |
| POM | 19.07 | +0.10 | +0.53% | 4.322B |
| POL | 13.23 | +0.23 | +1.77% | 1.158B |
| PODD | 18.43 | -0.08 | -0.43% | 880.71M |
| PNY | 30.30 | +0.63 | +2.12% | 2.146B |
| PNX | 1.61 | -0.02 | -1.23% | 189.59M |